APC mRNA sequence for inhibiting formation of FAP adenoma and application of APC mRNA sequence
The invention belongs to the technical field of biological medicine, and particularly relates to an APC mRNA sequence for inhibiting FAP adenoma formation. The sequence of the APC mRNA is shown as SEQ ID NO.1. The APC mRNA can down-regulate the expression level of beta-catenin protein and inhibit the proliferation of APC mutant cells, has no obvious influence on the proliferation of normal intestinal epithelial cells, and has the advantages of high specificity, small administration dosage, continuous expression and the like. The APC mRNA sequence provided by the invention provides a new thought for prevention and treatment of familial adenomatous polyposis, and also provides a potential therapeutic target for a normal epithelial-adenoma-adenocarcinoma evolution process of colorectal cancer. On the basis, a candidate strategy is provided for research and development of subsequent preparation of anti-tumor biological agents, and the method has a good commercial prospect..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 24. Nov. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
DONG JIAN [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-11-24, Last update posted on www.tib.eu: 2024-02-05, Last updated: 2024-02-09 |
|---|
| Patentnummer: |
CN117106787 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA019165536 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA019165536 | ||
| 003 | DE-627 | ||
| 005 | 20240209083522.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240209s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA019165536 | ||
| 035 | |a (EPA)CN117106787 | ||
| 035 | |a (EPA)88797715 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a DONG JIAN |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a APC mRNA sequence for inhibiting formation of FAP adenoma and application of APC mRNA sequence |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-11-24, Last update posted on www.tib.eu: 2024-02-05, Last updated: 2024-02-09 | ||
| 520 | |a The invention belongs to the technical field of biological medicine, and particularly relates to an APC mRNA sequence for inhibiting FAP adenoma formation. The sequence of the APC mRNA is shown as SEQ ID NO.1. The APC mRNA can down-regulate the expression level of beta-catenin protein and inhibit the proliferation of APC mutant cells, has no obvious influence on the proliferation of normal intestinal epithelial cells, and has the advantages of high specificity, small administration dosage, continuous expression and the like. The APC mRNA sequence provided by the invention provides a new thought for prevention and treatment of familial adenomatous polyposis, and also provides a potential therapeutic target for a normal epithelial-adenoma-adenocarcinoma evolution process of colorectal cancer. On the basis, a candidate strategy is provided for research and development of subsequent preparation of anti-tumor biological agents, and the method has a good commercial prospect. | ||
| 650 | 4 | |a bio | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a SHI WENJUN |4 aut | |
| 700 | 0 | |a LI YUNFENG |4 aut | |
| 700 | 0 | |a YANG JUN |4 aut | |
| 700 | 0 | |a CHENG XIANSHUO |4 aut | |
| 700 | 0 | |a LUO PEI |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 24. Nov. |
| 773 | 1 | 8 | |g year:2023 |g day:24 |g month:11 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/88797715/publication/CN117106787A1?q=CN117106787 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 24 |c 11 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 24 |c 11 | ||